PunditScore
Pundits › Myles Minter
MM

Myles Minter

Compare →
Biotech Equity Research Analyst at William Blair
Financial & Wall StreetBiotechnology

Myles Minter is a Biotech Equity Research Analyst at William Blair, specializing in the analysis of biotechnology companies. With a Ph.D. in neuropharmacology and a background in biomedical science, he transitioned from a postdoctoral role at the University of Chicago to equity research, where he focuses on commercial-stage biotech firms addressing high unmet medical needs.

No chart yet. A chart needs 8 resolved predictions, and Myles has 1. The predictions themselves are below.

SORT
STILL OPEN
?
2026 readouts across CRISPR, base editing, RNA editing and DNA writing will be significant.
Due Dec 31, 2026April 20, 2026gene editingbiotechPending
—
SCORE
⌄
?
2026 catalysts span base editing, RNA editing, allogeneic CAR-Ts, and DNA writing.
Due Dec 31, 2027April 20, 2026gene editingbiotechPending
—
SCORE
⌄
RESOLVED · NEWEST FIRST
✓
Vertex Pharmaceuticals will experience future earnings growth supported by an updated financial model that reflects an increase in the projected GAAP EPS.
May 3, 2024call #1biopharmaceuticalsfinancial growthCorrect
85
SCORE
⌄

Still open · 2

THE FRONT EDGE

Not resolved, so they don’t move the score.

?
2026 readouts across CRISPR, base editing, RNA editing and DNA writing will be significant.
Due Dec 31, 2026Said April 20, 2026gene editingbiotech
No market prices this claim
?
2026 catalysts span base editing, RNA editing, allogeneic CAR-Ts, and DNA writing.
Due Dec 31, 2027Said April 20, 2026gene editingbiotech
No market prices this claim